Agile Therapeutics, Inc. filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3399 USD | 0.00% |
|
-5.08% | -82.57% |
May. 15 | Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
1st Jan change | Capi. | |
---|---|---|
-82.57% | 2.33M | |
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt